Home Cart Sign in  
Chemical Structure| 871026-44-7 Chemical Structure| 871026-44-7

Structure of TAK-285
CAS No.: 871026-44-7

Chemical Structure| 871026-44-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-285 is a dual HER2 and EGFR (HER1) inhibitor with IC50 of 17 nM and 23 nM, > 10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TAK-285

CAS No. :871026-44-7
Formula : C26H25ClF3N5O3
M.W : 547.96
SMILES Code : CC(C)(O)CC(NCCN1C=CC2=NC=NC(NC3=CC=C(OC4=CC=CC(C(F)(F)F)=C4)C(Cl)=C3)=C21)=O
MDL No. :MFCD22124520
InChI Key :ZYQXEVJIFYIBHZ-UHFFFAOYSA-N
Pubchem ID :11620908

Safety of TAK-285

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TAK-285

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR/HER1, IC50:23 nM

  • HER2/ErbB2

    HER2, IC50:17 nM

  • ErbB4

    HER4, IC50:260 nM

  • HER2

    HER2, IC50:17 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MES-SA/DX-5 10 µmol/L 1.5 h Evaluate whether TAK-285 is a Pgp substrate, showing that TAK-285 is not a Pgp substrate. J Cancer. 2013 Aug 16;4(7):557-65.
MRC-5 20.0 µmol/L 3-7 days Evaluate the inhibitory effect of TAK-285 on MRC-5 cell growth, showing an IC50 of 20.0 µmol/L. J Cancer. 2013 Aug 16;4(7):557-65.
A-431 1.1 µmol/L 3-7 days Evaluate the inhibitory effect of TAK-285 on A-431 cell growth, showing an IC50 of 1.1 µmol/L. J Cancer. 2013 Aug 16;4(7):557-65.
BT-474 0.017 µmol/L 3-7 days Evaluate the inhibitory effect of TAK-285 on BT-474 cell growth, showing an IC50 of 0.017 µmol/L. J Cancer. 2013 Aug 16;4(7):557-65.
22RV1 prostate carcinoma cells 0.8-2.8 nM 24 hours To evaluate the antiproliferative effects of TAK-285 derivatives on 22RV1 cells, showing IC50 values in the range of 0.8-2.8 nM. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2202358.
PC3 prostate carcinoma cells 1.0-7.3 nM 24 hours To evaluate the antiproliferative effects of TAK-285 derivatives on PC3 cells, showing IC50 values in the range of 1.0-7.3 nM. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2202358.
MDA-MB-175VII cells 1 μmol/L 2 hours To evaluate the effect of TAK-285 on phospho-HER3 levels, results showed TAK-285 reduced phospho-HER3 levels Oncoscience. 2014 Mar 24;1(3):196-204.
SK-BR-3 cells 1 μmol/L 2 hours To evaluate the effect of TAK-285 on phospho-HER2 and phospho-HER3 levels, results showed TAK-285 reduced phospho-HER2 and phospho-HER3 levels Oncoscience. 2014 Mar 24;1(3):196-204.
BT-474 cells 1 μmol/L 2 hours To evaluate the effect of TAK-285 on phospho-HER2 and phospho-HER3 levels, results showed TAK-285 reduced phospho-HER2 and phospho-HER3 levels Oncoscience. 2014 Mar 24;1(3):196-204.
Human breast cancer cell lines 0.011~17 μmol/L To determine the inhibitory effect of TAK-285 on cell growth, an inverse correlation was found between IC50 values and HER2 or HER3 gene expression Oncoscience. 2014 Mar 24;1(3):196-204.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nu/nu mice BT-474 breast cancer xenograft model Oral 100 mg/kg Twice daily for 2 weeks Evaluate the antitumor activity of TAK-285 in the BT-474 breast cancer xenograft model, showing a T/C value of 29%. J Cancer. 2013 Aug 16;4(7):557-65.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.82mL

0.36mL

0.18mL

9.12mL

1.82mL

0.91mL

18.25mL

3.65mL

1.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories